Latest Commercialisation News

Impact Minerals’ 50%-owned Alluminous Pty Ltd advances its proprietary HiPurA® High Purity Alumina technology with new leadership and pilot plant commissioning, attracting strong customer interest.

Ainsworth Game Technology reported a steady profit before tax of $13.9 million for the first half of 2025, supported by a 25% revenue increase driven by strong North American and Asia Pacific markets.

Wide Open Agriculture has launched a pre-feasibility study for a large-scale lupin protein facility in Western Australia, aiming to establish a new global food category and reduce production costs. This move marks a pivotal step toward commercial scale and global leadership in sustainable plant-based proteins.

AnteoTech has appointed Merrill Gray as its new Managing Director and CEO following a successful interim period, while issuing over 22 million shares to staff under its FY2025 incentive program.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

Amplitude Energy has delivered record production and earnings in FY25, driven by operational improvements and a strategic joint venture for the East Coast Supply Project.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.

Bass Oil reported steady oil production in July alongside progress in acquiring the Vanessa gas field and advancing deep coal commercialisation efforts.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Rhythm Biosciences is raising up to $3.75 million through a share placement to fund the launch of its ColoSTAT® colorectal cancer diagnostic and accelerate commercialization of its geneType™ portfolio.